6 results about "Hsp90 inhibitor" patented technology

The present disclosure is directed to Hsp90 inhibitors having the Formula (I), subformulae thereof, pharmaceutically acceptable salts, stereoisomer, or tautomer thereof, and methods of use thereof.

The present application belongs to the field of biological medicine, and particularly relates to a pharmaceutical composition containing HSP90 inhibitor and application thereof, wherein the composition contains an effective amount of HSP90 inhibitor and a pharmaceutically acceptable carrier. The pharmaceutical composition containing HSP90 inhibitor has a significant therapeutic effect on esophageal cancer, lung cancer, gastric cancer and liver cancer cells, and has less toxicity to normal cells. The HSP90 inhibitor composition has a significant inhibitory effect on the proliferation and migration of esophageal cancer cells, can significantly increase the expression of Cleaved-PARP, and promotes the apoptosis effect. The pharmaceutical composition containing HSP90 inhibitor can improve the bioavailability of the drug, and can produce a synergistic effect on the drug efficacy. The therapeutic effect on tumor drug resistance is obviously better than that of single drug use.

The invention discloses an anti-tumor multifunctional membrane bionic HSP90 nano inhibitor as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention aims to solve the technical problems that the existing HSP90 inhibitor is poor in selectivity, high in systemic toxicity and limited in single-mode treatment effect, and the cancer cell antioxidant mechanism in the existing CDT / PDT combined therapy weakens the ROS anti-tumor effect. According to the key point of the technical scheme, the invention provides the multifunctional membrane bionic HSP90 nano inhibitor consisting of a chlorophyllin-iron complex (having HSP90 inhibition, photosensitivity and Fenton catalysis functions), a calcium carbonate nano core and a tumor cell membrane coating layer.

The application provides a kind of targeted nano-drug based on pH response protein self-assembly and a preparation method thereof, and belongs to the technical field of nanomaterials.The application first activates photosensitizer Ce6 and peptide segment cNGQGEQc respectively, then couples with CAT respectively, to prepare photosensitizer-protein conjugate and photosensitizer-peptide segment conjugate, and then obtains the nano-probe through the self-assembly behavior of photosensitizer-protein conjugate, photosensitizer-peptide segment conjugate, hydrophilic silver sulfide quantum dots and HSP90 inhibitor.The nano-probe not only realizes the drug release and NIR-II imaging guidance of tumor microenvironment response, but also relieves hypoxia and inhibits heat resistance synchronously, truly realizes the synergistic amplification effect of PDT / PTT, and provides a promising strategy for precise and efficient treatment of NSCLC.

The present invention provides inhibitors of proteins that activate the erythroblast transformation-specific proto-oncogene (2)(ETS2), and their use in the treatment or prevention of inflammatory and / or autoimmune diseases. Inhibitors are generally MEK inhibitors, HSP90 inhibitors, RAF inhibitors, SRC inhibitors, and / or ERK inhibitors. The present invention also encompasses diagnostic methods and methods for screening for agents that reduce macrophage activation.

This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.